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Abstract. Angiotensin converting enzyme (ACE) in- 
hibitors are extensively used for the treatment of hyper- 
tension, to decrease proteinuria, and to mitigate hyperfil- 
tration. These drugs now have been shown to be fetotoxic 
causing profound fetal hypotension, renal tubular dysplasia, 
anuria-oligohydramnios, growth restriction, hypocalvaria, 
and death when used in the second and third trimesters of 
pregnancy. We recommend that ACE inhibitors not be used 
in pregnancy. However, if a child is born with ACE in- 
hibitor fetopathy, aggressive therapy with dialysis to re- 
move the inhibitor may mitigate the profound hypotensive 
effects. Therapy will depend on the specific ACE inhibitor, 
and care recommendations cannot be generalized for the 
entire class of drugs as their protein binding and volume of 
distribution differ substantially. 
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Introduction 
Since their first discovery in 1965, angiotensin converting 
enzyme (ACE) inhibitors have come to be regarded as a 
major advance in the treatment of hypertension [1]. Pre- 
vious classes of antihypertensives such as J]-adrenergic 
receptor blockers and diuretics tend to increase peripheral 
resistance and alter the metabolism of electrolytes, glucose, 
and lipids. ACE inhibitors, on the other hand, decrease 
vascular resistance, improve glucose handling, and control 
left ventricular mass [1]. ACE inhibitors produce little 
change in heart rate or cardiac output. They also have 
provided an improved quality of life for the young hy- 
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pertensive patient especially when compared with 
[~-blockers or other central nervous system suppressants 
which may cause decreased motivation, depression, and 
decreased school performance. The fact that ACE inhibitors 
impede the progression of nephropathy associated with 
diabetes, both in type I and II, made it probable that large 
numbers of women of childbearing age could be placed on 
these medications [2]. 
The ACE inhibitors are competitive inhibitors of kini- 
nase II. They affect both the angiotensin/aldosterone and 
bradykinin/prostaglandin systems (Fig. 1). ACE inhibitors 
affect the renal microvasculature resulting in dilatation of 
glomerular efferent arteries and a decrease in filtration 
pressure. Excretion of ACE inhibitors is principally renal. 
They are also known to cross the human placenta. In the 
fetus, it is presumed that these agents are at least partly 
excreted into the amniotic fluid and recycled by swallow- 
ing. The renin-angiotensin system is critically important 
under conditions of low renal perfusion pressure such as 
exist in the fetus. Angiotensin-mediated arteriolar resis- 
tance is essential to the maintenance of glomerular filtra- 
tion and production of urine. Activation of bradykinin by 
suppression of angiotensin II can compromise the glomer- 
ular filtration rate by virtue of bradykinin's vasodilatory 
effect on the efferent arteriole (Fig. 1). Angiotensin II also 
may have a specific action on growth of its target tissues. 
Cells such as the adrenocortical cells can be induced to 
divide by angiotensin II. The mechanism by which angio- 
tensin II induces hypertrophy of its target tissues is largely 
unknown but may involve a direct action on proto-onco- 
gene synthesis or an indirect action on growth factor se- 
cretion [3]. 
Animal studies 
Reports of fetal wastage in ACE inhibitor-exposed experi- 
mental animals occurred as early as 1980 [4]. The first 
adverse outcome in a human pregnancy was reported in 
1981 and subsequently other cases implicating both cap- 
topril and enalapril as fetotoxins were reported in 1982 by 
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]'able 1. Reports of angiotensin converting enzyme (ACE) inhibitor 
fetopathy in the literaturea 
n I U G R  Oligohy- Hypotension Mortality 
dramnios anuria 
Case reports 14 9/14 10/14 9/14 8/14 
Case series 42 11/38 4/11 4/11 6/42 
Totals 56 20/52 14/25 13/25 14/56 
36% 56% 52% 25% 
IUGR, Intrauterine growth retardation 
a Compiled from Pryde et al. [13] 
Guignard [5], and 1984 by Boutroy et al. [6], Caraman et al. 
[7], and Rothberg and Lorenz [8]. Animal models of ACE 
inhibitor fetopathy are relatively confusing. In rats, the 
development of the renin-angiotensin system is very late in 
gestation, and, therefore, results from rat studies have 
uniformly failed to reveal any adverse effects on fetuses. In 
late gestation and lactation studies in which ACE inhibitor 
exposure occurred during the critical period of rat fetal 
renin synthesis, neonates did demonstrate adverse effects, 
with pup deaths occurring during lactation. 
Rabbits are particularly sensitive to ACE inhibitors; 
administration of 2 - 5  mg/kg per day of captopril in 
pregnant rabbits yielded pregnancy loss rates from 37% to 
92% [4, 9]. Rabbit fetuses in late gestation are highly 
sensitive to toxic effects of ACE inhibitors. When ad- 
ministered in a human therapeutic range, ACE inhibitors 
produce fetal deaths in middle to late gestation with a peak 
effect on gestational day 26 (term gestation = 47 days) 
[9, 10]. 
The chronically catheterized sheep model was used by 
Broughton-Pipkin et al. in 1982 [9] and was shown to be an 
excellent model to study cardiovascular and renal changes 
occurring in the maternal and fetal compartments during 
pregnancy. When captopril was given to sheep from ge- 
station day 119-133 (term = 147), maternal blood pressure 
was transiently reduced and returned to normal within 2 h. 
However, fetal blood pressure remained reduced for up to 
2 days and seven of eight lambs were stillborn. 
A recent study utilizing a crossover design in 12 se- 
quentially pregnant baboons treated with placebo versus a 
therapeutic dose of enalapril demonstrated a high rate of 
affected fetuses. Of 13 fetuses in the enalapril arm, 8 had 
adverse outcomes, with 3 of the 13 having fetal deaths 
versus 0 adverse outcomes or deaths in the placebo arm. No 
gross abnormalities were noted on autopsy of the dead 
fetuses other than low birth weight. No histology was 
done [11]. 
Clinical studies 
Data concerning adverse effects of ACE inhibitors on 
human fetuses were first noted in 1981 by Duminy and 
Burger [12]. Warnings about the use of ACE inhibitors in 
human pregnancy appeared in the literature as early as 
1985. Despite this information, reviews of ACE inhibitors 
often made no mention of the adverse fetal effects; and 
certainly, in the obstetrical community, there did not seem 
to be widespread knowledge of fetotoxicity. In 1993, Pryde, 
et al. [13] summarized affected cases from the literature 
and added 3 more (Table 1). Subsequent petitioning of the 
Food and Drugs Administration (FDA) concerning these 
cases led to an FDA bulletin on March 16, 1992 empha- 
sizing the warning information regarding use of ACE in- 
hibitors in pregnancy. A box warning was required for all 
ACE inhibitors which stated that when ACE inhibitors 
were used in pregnancy during the second and third tri- 
mesters they could cause injury and even death to the de- 
veloping fetus. There has been no absolute proof that first 
trimester exposure has adverse fetal effects; however, Piper 
et al. [14] did report one instance of encephalocele occur- 
ring in a fetus with first trimester exposure. The most 
common effects reported are second and third trimester 
onset of oligohydramnios and growth restriction followed 
by a neonatal course associated with prolonged profound 
hypotension and anuria. If the oligohydramnios is severe 
enough, a Potter-like sequence and pulmonary hypoplasia 
can occur. Hypocalvaria also has been reported and thought 
to be secondary to poor perfusion of plate-like bone 
structure in the skull [15]. Although persistence of patent 
ductus arteriosus may have an association, the high rate of 
this defect in premature infants makes the data incon- 
clusive. Pathological examination of the kidneys in 10 cases 
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Table 2. Data from three patients at University of Michigan Medical Center with ACE inhibitor fetopathy 
Maternal Infant gestation Signs and Dialysis ACE levels ACE levels Lisinopril Outcome 
disease Birth weight symptoms before dialysis after dialysis level (ng/ml) 
Medication 
Case 1 18 years 32 weeks Oligohydramnios 2.5%-4.25% 7.5 gmol/ml 19.5 gmol/ml serum 6.3 
primigravida 1,480 g IUGR 20 ml/kg (normal dialysate 3.3 
renal HTN hypocalvaria q 1/2 ° - q  3 ° 20-30 gmol/ml) 
lisinopril hypotension 
renal failure Dialysis/plasma 
normal-sized = 0.52 (ratio of 
kidneys lisinopril) 
32 weeks Oligohydramnios 2.5% 1.1 U/ml 9.2 U/ml Death 
980 g IUGR 20 ml/kg (normal = day 9 
hypocalvaria q 1/2 ° - q  1 ° 20-30 U/ml) from 
hypotension perforated 
renal failure bowel 
normal-sized 
kidneys 
33 weeks Oligohydramnios Death 
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showed normal to large-sized kidneys with renal tubular 
dysgenesis. Barr et al. [15] have made specific re- 
commendations that ACE inhibitors be considered feto- 
pathic instead of teratogenic in that the effects are sec- 
ondary to hypotension and poor perfusion without evidence 
that there is actual early malformation of the fetus. 
There now have been approximately 56 cases of ACE 
fetopathy in the literature [13]. These infants are affected 
by intrauterine growth retardation, oligohydramnios, hy- 
potension and anuria, with a mortality rate of approxi- 
mately 25%. Three cases in our institution, previously re- 
ported [13], exemplify the classic findings. These are ta- 
bulated in Table 2. 
Case reports 
Case 1 
This was the 32-week, 1,480-g infant of  an 18-year-old prima gravida 
who had been treated with lisinopril throughout her pregnancy for 
renovascular hypertension. Spontaneous rupture of membranes  and 
fetal distress led to the premature delivery of  the infant who was noted 
to have severe oligohydramnios,  intrauterine growth retardation, hy- 
pocalvaria, profound hypotension, and renal failure with a renal ul- 
trasound that showed normal-sized kidneys. ACE levels prior to dia- 
lysis were 7.4 gmol/ml,  normal being 2 0 - 3 0  gmol/ml.  After standard 
peritoneal dialysis was started, these levels rose to 19.5 gmol/1. Lisi- 
nopril levels in the serum were 6.3 ng/ml while those in the dialysate 
were 3.3 ng/ml. Renal biopsy at 4 weeks showed acute tubular necrosis 
Table 3. Pharmacokinetics of ACE inhibitors a 
ACE Onset/ Time to Percentage Active t l /2 Normal t l /2 Impaired 
duration (h) peak serum absorbed metabolite renal function renal function 
levels (h) 
Elimination 24 h % protein Dialyz- Volume of 
bound ability distribution 
Total Unchanged 
Benazepril 1/24 0.5-1 37% Benazeprilat 10-11 h Prolonged 
Captopril 0,25/dose- 0.5-1.5 75% <2  h 3.5-32 h 
related 
Enalapril 1/24 0.5 - 1.5 60% Enalaprilat 1.3 b NA 
(enalaprilat 
3-4)  
Enalaprilat 0.25/~ 6 NA NA 11 h Prolonged 
Fosinopril 1/24 ~3  36% Fosinoprilat 12h Prolonged 
(Fosinoprilat 
IV) 
Lisinopril 1/24 ~7  25% 12 h Prolonged 
Quinapril 1/24 1 60% Quinaprilat 2 h Prolonged 
(Quinaprilat) 
Ramipril l -2 /24 1 50%-60% Ramiprilat 1 -2  h Prolonged 
(ramiprilat (Ramiprilat) 
2-4)  
NA trace 95% yes 0.12 1/kg 
>95% 40%-50% 25%-30% yes 0.7 1/kg 
in urine 
94% urine 54% in 50%-60% yes 0.375 1/kg 
and feces urine (40% 
enalaprilat) 
NA > 90% yes 0.375 1/kg 
(urine) 
50% urine negligible 95% no 0.14 1/kg 
50% feces 
NA urine 100% small yes 1.8 1/kg 
80% urine trace 97% no 
37% feces 
80% urine <2% 56%-73% unknown unknown 
40% feces 
NA, Not available 
a Compiled from Facts and Comparisons,  Inc., St. Louis, Mo. USA, January 1994 and direct communicat ion with innovator companies 
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and renal tubular dysplasia. This infant was supported on dialysis until 
renal transplant occurred at 22 months of age. The child had a suc- 
cessful transplant and is now stable at 4 years of age with normal 
cognitive development. His severe intrauterine growth retardation was 
never completely corrected; and, although he resumed a normal growth 
velocity after transplant, he is still -4  SD below the curve and is a 
candidate for growth hormone therapy. 
Case 2 
This was a 32-week, 980-g infant born of a 30-year-old prima gravida 
who had essential hypertension which initially had been treated with 
labetalol. She was switched to enalapril with the belief that it would be 
a better drug during pregnancy. This infant was also born with oli- 
gohydramnios, intrauterine growth retardation, hypocalvaria, hypo- 
tension, and renal failure with normal-sized kidneys. His ACE level 
before dialysis was 1.1 gmol/ml, normal being 20-30 gmol/ml. ACE 
levels increased with peritoneal dialysis, but the baby remained pro- 
foundly hypotensive and had necrotizing enterocolitis, perforated 
viscus, and subsequently died on day 9 of life. At autopsy, the baby had 
hypocalvaria. The kidneys were normal sized with tubular dysplasia. 
The lungs were hypoplastic. 
real size on renal ultrasound but that there is profound renal failure 
with little urine output. Clearly, early fetal loss with severe prematurity 
could be occurring with an ACE inhibitor exposure, and may be 
missed. Once a child is noted to have fetal toxicity, management 
should include assessment of type of drug. Decisions made about 
method of dialysis will be dependent on the characteristics of that 
particular ACE inhibitor. Highly protein-bound drugs are less amen- 
able to clearance by dialysis, but exchange transfusion while on he- 
modialysis could be a helpful therapy. 
The best strategy to prevent ACE fetopathy is to aggressively 
educate physicians and the public that these drugs should not be used 
during the second and third trimester of pregnancy. If the drug is 
inadvertently administered during this period, it is estimated that 50% 
of the infants will be affected and 25% will die. The drug should be 
stopped if at all possible. As new drugs are manufactured that mimic 
the effect of ACE inhibitors, such as ACE receptor blockers, the same 
type of fetal effects could be anticipated. Extensive animal testing in 
sheep and higher primates should be performed in order to predict 
toxicity. 
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Case 3 
This was a 33-week gestation infant who had been noted at 19 weeks 
of gestation to have severe oligohydramnios. She was the child of a 
26-year-old woman with an 8-year history of systemic lupus er- 
ythematosus whose hypertension was controlled with a combination of 
captopril, 150 mg every day, furosemide, and atenolol. Oligohy- 
dramnios and growth restriction were noted beyond the 14th week of 
gestation. The 1,440-g female was delivered from a breech presenta- 
tion and had Apgar scores of 1 and 5, was basically unresponsive to 
support and died at 14 h of life with normal-sized kidneys but no urine 
output. This baby also had significant hypocalvaria. Renal histo- 
pathology showed normal-sized kidneys with renal tubular dysplasia. 
Pharmacokinetics of ACE inhibitors 
There are now seven ACE inhibitors marketed in the United States. 
They include enalapril, captopril, lisinopril, ramipril, fosinopril, ben- 
zapril, and quinapril. Characteristics of these drugs are listed in Table 3, 
reflecting their protein binding, volume of distribution, and potential 
dialyzability. Both fosinopril and quinapril are very highly bound to 
plasma proteins and, therefore, dialysis would not be predicted to be 
helpful in children who have been exposed to these drugs. Exchange 
transfusions may be helpful but no such cases have been reported. 
Enalapril, captopril, and lisinopril are predicted to be somewhat dia- 
lyzable. Our data in the infant who received lisinopril and was suc- 
cessfully dialyzed demonstrate that ACE activity was lower than 
normal prior to dialysis and subsequently returned to normal level after 
dialysis. Lisinopril levels in the serum were approximately twice the 
level of those in the dialysate after a 1-h pass. As ACE levels returned 
to normal, urine output increased from 0.2 ml/kg per hour up to 2.5 ml/ 
kg per hour. This child then continued to have urine output although he 
was never adequately able to regain full kidney function. Early he- 
modialysis would have been better than peritoneal dialysis to facilitate 
the clearance, but the infants were too hypotensive to attempt hemo- 
dialysis. 
Summary 
In summary, ACE inhibitors have been shown to cause fetal toxicity, 
including profound fetal hypotension, anuria, oliguria, and growth 
restriction. Animal data have also documented these effects. Re- 
cognition of the syndrome would include noting the kidneys are nor- 
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